Oral XXXX versus Combined Oral Contraceptives for Adolescent Heavy Menstrual Bleeding: A Pilot Study.

@entity1 @entity548 @entity190 @entity927 @entity7280
STUDY OBJECTIVE: To compare the efficacy of oral @entity927 (TA) with combined @entity7280 (COC) in reducing @entity190 ( @entity190 ) and improving quality of life in adolescent @entity548 ( @entity548 ). DESIGN, SETTING, AND @entity1 : A prospective randomized crossover trial with 17 postmenarchal @entity1 aged 21  years and younger with @entity548 who were seen at our institution. INTERVENTIONS: @entity1 were randomized to group A (TA arm) or group B (COC arm), each for 3 cycles, with crossover to the second arm after 1-month washout. MAIN OUTCOME MEASURES: The primary end points were difference in improvement in @entity190 and QOL, from baseline to end of each therapy. RESULTS: Seventeen @entity1 were enrolled (mean age 14.2  years, range 11.7 to 16.8  years). Nine @entity1 completed both arms; 8 @entity1 withdrew from the study due to adverse events or noncompliance. Compared with baseline, significant improvement (P  <  .05) was demonstrated by TA and COC in @entity190 (mean Pictorial Blood Assessment Chart score decrease: TA, 536.4; COC, 430.6) and quality of life (mean Pediatric Quality of Life Inventory(TM) version 4.0 Generic Scales score increase: TA, 15.6; COC, 16.75), but no significant difference was noted between TA and COC (P  >  .05). There was statistically significant reduction in the length of menstrual cycle for COC only (mean reduction 5.3  days; P  =  .04) and not for TA (P  =  .18). Ten @entity1 (58%) experienced adverse events that were possibly drug related (TA: n  =  3, 30%; COCP: n  =  7, 64%). CONCLUSION: In this pilot study, oral TA appeared as efficacious as COC in the management of adolescent @entity548 by reducing @entity190 and improving quality of life.
